ELAFY supported OCON Therapeutics in securing a $10 million funding round to advance next-generation solutions in women’s health, focused on the treatment of uterine pathologies. The round was led by RH Capital, with participation from Features Capital, Astia Angels, Exerte Partners, and additional support from the Israeli Innovation Authority. ELAFY played an active role throughout the fundraising process, including: development and refinement of the investor pitch deck par